Raegan O'Lone

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With<i>ERBB2</i>Amplification or<i>ERBB2/3</i>Mutations: Results From the TAPUR Study

R. Gupta, Funda Meric‐Bernstam, Michael Rothe et al. · JCO Precision Oncology · 2022 · 61 citations

Medicine, Oncology, Pharmacology +17

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With<i>BRAF</i>Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Kelsey Klute, Michael Rothe, Elizabeth Garrett‐Mayer et al. · JCO Precision Oncology · 2022 · 27 citations

Medicine, Oncology, Pharmacology +17

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study

Eugene R. Ahn, Michael Rothe, Pam K. Mangat et al. · JCO Precision Oncology · 2023 · 20 citations

Medicine, Oncology, Pharmacology +16

Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.

Funda Meric‐Bernstam, Michael Rothe, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2022 · 13 citations

Medicine, Oncology, Pharmacology +15

Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study

Eddy S. Yang, Susan Halabi, Michael Rothe et al. · JCO Precision Oncology · 2023 · 12 citations

Medicine, Oncology, Pharmacology +17